Odimont AB 200mg/10mg Tablet is a combination medication containing Acebrophylline 200mg and Montelukast 10mg, indicated for the management of respiratory conditions characterized by bronchoconstriction and inflammation, such as chronic obstructive pulmonary disease (COPD) and asthma. Acebrophylline, a xanthine derivative, acts as a bronchodilator by relaxing bronchial smooth muscles and possesses mucolytic and anti-inflammatory properties, facilitating improved airway clearance and reducing airway hyperresponsiveness. Montelukast, a leukotriene receptor antagonist, selectively inhibits cysteinyl leukotriene receptors, thereby preventing leukotriene-mediated bronchoconstriction, inflammation, and mucus production. The synergistic action of these agents provides comprehensive control of airway obstruction and inflammation, enhancing pulmonary function and symptom relief. Odimont AB is administered orally, typically once daily, with dosage tailored according to clinical response and physician guidance. It is generally well tolerated; however, potential adverse effects may include headache, gastrointestinal disturbances, and hypersensitivity reactions. Caution is advised in patients with hepatic impairment or known hypersensitivity to components. This combination therapy offers a convenient and effective option for patients requiring both bronchodilation and anti-inflammatory treatment to improve respiratory outcomes and quality of life. Regular monitoring and adherence to prescribed therapy are essential for optimal benefit.